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5I Foreword
Twenty years after the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
published its first extended annual report on the state of the drugs problem in the European 
Union, our work is gaining new impetus with the adoption of the EMCDDA Strategy 2025.
Our long-term strategic vision states unambiguously our ambition to contribute to a healthier 
and more secure Europe by providing sound evidence for policies and actions on drugs. This 
vision has been built on a structured reflection and analysis: of the lessons we have learned in 
more than 20 years of existence; of the changing drugs phenomenon; and of developments in 
the institutional and international environment.
All the members of the Management Board, Scientific Committee, Reitox network of national 
focal points and staff of the Agency have been consulted and involved in the drafting of this 
strategy. Their input has been invaluable and has helped build shared ownership of a document 
to which we will refer up until 2025.
To be successful, the EMCDDA needs more than ever the support of its key partners and expert 
networks, starting with the Reitox network, but also including the EU Member States in their 
double capacity as key stakeholders of the agency and main data and information providers. Our 
communication with professionals working in the drugs field, researchers, civil society and those 
affected by the drugs problem is also very important, as our work aims ultimately to reduce the 
burden of drugs on society and on those who are more vulnerable.
This strategy comes at a very important time for the agency and for the European Union: in 
a period when the European project is coming under increasing internal and external pressure, it 
is our duty to respond with a clear affirmation of the added value and impact of our work for our 
stakeholders and for people living in Europe.
Within the context of the EMCDDA’s role and areas of competence, this strategy will guide us to 
produce information that makes a difference.
We hereby invite all our partners and stakeholders to join us in this endeavour and to help us 
contribute as much as we can to a healthier and more secure Europe.
Laura d’Arrigo Alexis Goosdeel 
Chair of the EMCDDA Management Board Director of the EMCDDA
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I Background — towards a long-term strategic approach
The Director, at the start of his mandate, presented a proposal to the Management Board to 
develop a long-term Strategy for the EMCDDA for the period 2016–2025, in consultation with its 
key stakeholders. This work has now been completed. The rationale for this new strategy and the 
detail on its vision, goals, strategic objectives and business drivers are set out below. A roadmap 
is also included, which creates a clear link between the Agency’s new strategic perspective and 
the planning and operational framework within which it works.
Identifying and building upon the EMCDDA’s core strengths was the starting point for 
developing this strategy. Over the last 20 years, the agency has established itself as the central 
European knowledge hub for drug-related information. The drugs problem is complex and 
multifaceted and part of its unique value is its comprehensive coverage of the issue, which 
ranges from public health and epidemiology to law enforcement, policy developments and 
legislation. The EMCDDA is now recognised within Europe, and internationally, as a centre of 
excellence in the drugs field; it is held in high regard by its stakeholders as a source of impartial 
information; and it has established a solid reputation as an important resource for practitioners 
working in the drugs area as well as for the scientific community.
We recognise these achievements but we remain mindful of the need to continue to strive to 
improve the value of our work for our stakeholders. We also recognise that we must accomplish 
this during a period in which Europe faces new health and security challenges, many of which 
affect drug use and drug-related problems. The drugs issue has changed in many important 
ways since the EMCDDA was established. This can be seen in the more complex and rapidly 
evolving drugs phenomenon we now face and in the new health and security problems this 
brings with it. It can also be seen in how Europe is responding to these developments, which has 
resulted in a more dynamic institutional, policy and legal environment.
To remain useful, our work must keep pace with the changes occurring in our external 
environment. As an information agency, we must pay attention to the evolving global information 
economy and be alert to how this may affect our established working practices. We must also 
assess how new information-seeking behaviours and technological developments will change 
the nature of the products and services we offer. This work must be done within an institutional 
environment where financial and human resources are likely to be at best stable, and potentially 
diminishing. The need to address these challenges provides both the context and the rationale 
for the new strategy, as it is only through adopting a forward-looking and more strategic 
approach that the agency can guarantee that it will continue to remain policy-relevant and 
provide added value to stakeholders in the years ahead.
In summary, this new strategy provides the overarching framework for ensuring, first, that the 
EMCDDA’s work continues to reflect the reality of the external environment that Europe faces 
with respect to drugs issues and the evolving needs of our stakeholders; and, second, that the 
EMCDDA’s substantive activities are supported by an internal business model which adopts 
a forward and integrated approach to planning, promotes appropriate and efficient working 
practices, and ensures that core processes are optimised.
7EMCDDA strategic  
and operational framework
The Agency operates within a regulatory and institutional 
framework which clearly defines its role and mandate, and 
establishes the framework for planning, implementing and 
reporting its activities. The basis for the definition of the 
mission and mandate of the EMCDDA is provided by the 
recast regulation of 12 December 2006 (1). This document 
provides the agency with both its mandate and its mission and 
forms the bedrock on which our strategy has been built. It 
therefore reflects and takes forward the key priorities that the 
recast regulation gives to the agency in the areas of core 
monitoring, best practice and knowledge exchange, 
maintaining a sensitive information system and responding to 
new psychoactive substances (NPS), and supporting policy at 
national and EU levels.
While the strategy is intended to provide the long-term 
perspective necessary to drive our work up to 2025, any 
long-term approach needs to be sensitive to changing 
circumstances. For this reason we have planned a mid-term 
review. This will allow the agency and the Management Board 
to assess progress made and adjust the strategy to take into 
account any important new internal or external developments. 
These include possible constraints or new elements arising 
from our institutional environment (2). It is important to note 
here the possible implications that a revision of the EMCDDA’s 
Regulation with respect to the Early Warning System on NPS 
may have on our work, and also that an external evaluation of 
the agency’s activities is scheduled for 2018.
We have developed a Roadmap to facilitate implementation of 
the strategy and its mid-term review. This roadmap identifies 
some top-level milestones that we expect to achieve by the 
end of 2020. Following an assessment by the Management 
Board of the implementation of the Roadmap 2016–20, it is 
envisaged that a new Roadmap will be adopted for the period 
2021–25.
Furthermore, as set out in the agency’s Financial Regulation, 
every year we will prepare and submit to the Management 
Board for adoption a detailed planning instrument called the 
Single Programming Document (SPD). The SPD defines the 
results expected from EMCDDA activities. The strategy and its 
roadmap will therefore be used to guide the development of 
(1) Available at: www.emcdda.europa.eu/html.cfm/index24218EN.html
(2) The most relevant ones are the results of the external evaluation of the EU 
Drugs Strategy and Action Plans, the new multiannual financial perspective, the 
recommendations of the external evaluation of the EMCDDA, the new European 
Commission, and the duration of the mandate of the Director.
the SPDs and ensure the tasks and priorities given to the 
agency in its regulation are successfully taken forward.
Together, the long-term strategy, its roadmap and the SPDs 
comprise the EMCDDA’s integrated strategic and operational 
framework (ISOF) (see Figure 1). This architecture provides the 
Management Board with the assurance that the documents it 
is required to adopt every year are fully grounded in the 
EMCDDA’s mandate and that they contribute to reaching the 
agency’s established long-term organisational objectives.
In implementing the strategy, the EMCDDA will take into 
account the possible risks which may occur in the external 
and the internal environment, and which may have an impact 
on the agency’s capacity to implement its activities. To that 
end, a corporate risk assessment exercise will be carried out 
every year and the findings will be presented in the SPDs.
| EMCDDA mission, vision and values
The Strategy 2025 presents mission and vision statements 
that show how the agency sees its role and the value of its 
work for its European and national stakeholders, and 
ultimately for EU citizens. These statements build on the 
EMCDDA’s Founding Regulation and are informed by the 
Strategy and Work Programme 2016–18 adopted by the 
Management Board in December 2015. A fundamental 
principle of good governance is that the EMCDDA’s work and 
activities are concentrated in the areas where we can provide 
maximum added value. Consequently the vision and mission 
statements identify the primary beneficiaries of our work and 
their information needs, and match this with an analysis of the 
main assets at our disposal to fulfil our mandate.
The mission and vision statements provide the framework 
within which the EMCDDA staff can situate their work and 
within which our stakeholders can see the added value of the 
agency and the rationale for products and services delivered. 
Values guiding how the organisation operates as a whole 
accompany these statements.
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| Mission
The EMCDDA exists to support evidence-based decisions and 
actions at EU and national levels by providing factual, 
objective, reliable and comparable information concerning 
drugs and drug addiction and their consequences. The 
EMCDDA’s mission is therefore grounded in the consensus 
that sound information is a prerequisite for developing 
effective policies in the drugs area.
The need for factual, objective, reliable and comparable 
information reflects a European consensus that, in a sensitive 
and complex policy area such as drugs, effective actions have 
to be based on evidence of the nature of the problem and 
what has been shown to work rather than on moral or value 
judgements. Moreover, cooperation, coordination and 
common action are facilitated by comparing, contrasting and 
sharing national experiences. The EMCDDA is committed to 
providing the information resources necessary for these 
objectives and we are proud that over the last two decades 
our work has both helped to support the development of 
a more rational and effective approach to drug problems 
across the EU and facilitated a more cohesive policy dialogue 
on this complex and important issue.
To achieve this, a central priority for our work remains 
maintaining, consolidating and further developing the quality 
and comparability of the data and information collected 
through the Reitox network of national focal points (NFPs) and 
other sources of information. Furthermore, to keep pace with 
developments and the needs of our stakeholders, the 
EMCDDA is committed to identifying and using appropriate 
complementary sources of information to keep our knowledge 
base up to date.
To achieve our mission, we have developed a systemic approach 
that brings together the human networks, processes and 
scientific tools necessary for collecting, analysing and reporting 
on all aspects of the European drugs phenomenon. The 
EMCDDA now offers a unique European resource that includes:
■■ A consolidated monitoring and reporting system with 
harmonised, standardised and comparable data series 
collected on a yearly basis since 1995 (five key 
epidemiological indicators extended recently with more 
comprehensive and robust data on drug supply). The 
backbone of this system is the Reitox network of NFPs, an 
established network of 28 EU Member States, Norway and 
Turkey that provides a direct link to national data and 
expertise.
■■ A multidisciplinary, multi-indicator and multimethod 
approach.
■■ An established set of core methods, supporting tools and 
data definitions to provide harmonised reporting.
■■ A proven track record of developing innovative approaches 
to data collection and analysis with capacity for the early 
detection and reporting of new trends.
FIGURE 1
The EMCDDA’s integrated strategic and operational framework (ISOF)
Founding regulation (recast)
Strategy 2025
Roadmap 2020 Roadmap 2025
Mission
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■■ An EU-wide early warning system on NPS and risk 
assessment capability (3).
■■ A growing extended network that includes the Western 
Balkans and selected neighbouring countries.
■■ A team of highly qualified and motivated staff committed to 
working in a European multicultural and multilingual 
environment.
In addition, the EMCDDA works in partnership with 
universities, research centres, scientific bodies and EU and 
international organisations. This has not only allowed the 
agency to maintain a close and ongoing understanding of 
developments in the research area, but also supported the 
development of European and international standards, and 
facilitated the reporting and interpretation of European data at 
international level.
| Vision
The EMCDDA’s vision is a healthier and more secure Europe 
through better-informed drug policy and action.
To do this effectively we must constantly strive to respond to 
the needs of our key stakeholders, which can be defined as:
■■ the EU institutions;
■■ national decision-/policymakers; and
■■ professionals working in the drugs field.
As the agency needs to prioritise activities that will deliver 
maximum value, we will provide our customers with tailored 
products and services that enable them to:
■■ have a strategic, situational and holistic understanding of 
the European drugs situation and its implications for public 
health and security;
■■ anticipate, identify and respond at an early stage to new 
threats and developments;
■■ adopt and implement effective interventions informed by 
sound evidence about the situation and what works;
■■ build and evaluate national and European policies and 
strategies.
(3) It is expected that in 2017 the new proposed legislation Regulation of the 
European Parliament and of the Council amending Regulation (EC) 
No 1920/2006 as regards information exchange, early warning system and risk 
assessment procedure on new psychoactive substances (COM/2016/0547 
final - 2016/0261 (COD)) will enter into force. This new legislation will strengthen 
the early warning system on NPS and the risk assessment mechanism.
Beyond meeting the information needs of our key 
stakeholders, to address our mandate we also need to engage 
with other stakeholders, which include academic institutions 
and researchers; the general public, civil society and those 
affected by drug problems; and international organisations 
and third countries.
| Values
The EMCDDA is committed to the European Union and its 
values. Beyond these, we have identified a set of core values 
to inform all aspects of our work, inspire our staff in their 
professional performance, inform our future policies and 
guide our interactions with stakeholders and partners.
Our four core values are the following:
Scientific excellence
The EMCDDA is the centre of scientific excellence in Europe 
for the collection and analysis of data for the production of 
knowledge on the drugs phenomenon to facilitate sound 
decision-making and research.
Integrity and impartiality
The EMCDDA is committed to respecting European ethical 
values and to accomplishing its mission objectively, 
impartially, independently, transparently and by promoting 
evidence-based methodologies and interventions.
Customer focus and service orientation
The EMCDDA is devoted to proactively serving its customers 
by anticipating their needs and by producing services and 
products to help them achieve their missions and perform 
their tasks.
Efficiency and sustainability
The EMCDDA pursues cost-effectiveness in the performance 
of its tasks and is committed to further enhancing 
performance. The EMCDDA has an ongoing commitment to 
ensuring its corporate sustainability and maximising benefits 
with respect to its social, economic and environmental impact.
EMCDDA STRATEGY 2025
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|  Goals, strategic objectives and business drivers
| Goals
The EMCDDA has two long-term goals: to contribute, firstly, to 
a healthier Europe and, secondly, to a more secure Europe. 
These core goals naturally form the two pillars on which the 
strategy is built: health and security. It is important to note 
that the multifaceted nature of the drugs problem means that 
these goals are interlinked and mutually complementary.
Moreover, the EMCDDA’s data collection model recognises 
that a holistic understanding of the drugs situation is 
dependent on multisource analysis. Thus health information 
sources are necessary for understanding some security-
related questions such as the quantification of drug markets; 
similarly, supply-side information can inform an analysis of 
important health topics. For example, the composition of 
drugs available on the market can be important for 
understanding patterns of morbidity and mortality.
An understanding of the agency’s role and the external 
environment within which it operates were important points of 
departure for the strategy. Drug policy is largely articulated at 
the European level through cooperation and coordination 
activities, and the success of our work depends on the 
conditions in the Member States. We are also committed to, 
and dependent on, maintaining successful partnerships with 
European and international organisations. One of our key roles 
is to be a catalyst facilitating more effective policies and 
actions that will be delivered by other parties. This is why we 
give central importance to identifying our customers’ needs, 
developing services and effective communication, as these all 
represent essential elements for our work to have impact.
| Strategic objectives
Each of the two long-term goals is articulated through four 
strategic objectives. These objectives identify at strategic level 
the main areas of focus for taking forward work in each pillar.
They were developed by bringing together an analysis of three 
key factors shaping the EMCDDA’s future work: first, the 
changing nature of the drugs phenomenon; second, the 
challenges that these changes bring to our current business 
model; and, third, the implications of these changes for the 
needs of our customers.
Each objective is accompanied by more specific action areas. 
These have been developed from an analysis of what is 
required in the medium to long term to achieve the strategic 
objectives. A description of the strategic objectives and their 
action areas is provided in the next sections and a more 
detailed presentation can be found in Annex 1.
In 2020, progress made in achieving the strategic objectives 
will be assessed against the key milestones defined in the 
roadmap. Based on the results obtained, and taking due 
account of the changes in the institutional environment and in 
the evolution of the drugs situation, the objectives may be 
revised and the roadmap adjusted for the period 2021–25.
| Business drivers
An important part of the work conducted to develop this 
strategy was a critical review of the strengths and weaknesses 
of the EMCDDA’s current business model, which was informed 
by an analysis of the challenges and opportunities arising from 
the external environment in which we operate. This exercise 
identified both strengths and potential weaknesses, and a set 
of business drivers has been developed to address them. 
These business drivers define the resources and processes 
that the EMCDDA must have in place, and the conditions that 
the organisation has to meet, to achieve our strategic 
objectives and attain our long-term goals. They are therefore 
core elements of our strategic approach because they 
pinpoint the key factors for successful delivery. A detailed 
description of the business drivers and their action areas is 
provided in the next sections and a summary presentation can 
be found in Annex 2.
The links between the business drivers, the strategic 
objectives and the long-term goals are illustrated in Figure 2 
and further developed in the next sections of the document.
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FIGURE 2
The EMCDDA’s strategic approach
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EMCDDA Strategy to 2025
| Goal 1: Contribute to a healthier Europe
Drug use and its consequences are an important direct cause 
of avoidable morbidity and mortality in the European Union. 
Indirectly, drug consumption is also associated with other 
health and social problems, resulting in greater policy and 
intervention challenges in these areas. The epidemics of 
heroin use which have historically affected many European 
countries have left behind an ageing cohort of problem drug 
users with considerable health needs.
This means that, overall, opioids still account for the greatest 
proportion of drug-related health costs, although to some 
extent this is changing. This is because contemporary drug 
problems are more dynamic and more complex than in the 
past. Stimulants, cannabis and new psychoactive substances 
(NPS) are all now major health concerns and causing 
substantial health costs across the European Union. Moreover, 
both acute and chronic drug problems are now commonly 
associated with the consumption of multiple substances 
(polydrug use, including alcohol and misused medicines). 
These changes are reflected in, and partly driven by, a more 
dynamic and globalised drug market.
The last two decades have seen a growth in our understanding 
of how to respond to drug problems and an acceptance by 
policymakers of the principle of investing in approaches that 
are shown to be effective. We are also entering a period in 
which a range of new approaches to tackling drug problems 
are likely to become available. Advances in fundamental 
sciences are resulting in new pharmacotherapies; applied 
research is resulting in new approaches to monitoring, 
prevention, treatment and harm reduction; and increased 
attention to the importance of implementation science and 
implementation systems is enhancing our understanding of 
how to translate research evidence into policies and 
programmes that can be successful in the various real-world 
settings in which they must be applied.
The multifaceted nature of drug problems and their interaction 
with other social and health challenges is also affecting the 
overall policy discussion on drug use and on the policy 
approaches adopted to reduce the negative health and social 
impacts of drug use on society. There is no common model 
here, but in general there is increasing interest in topics such 
as addressing drug use in a more holistic substance misuse 
and broader public health perspective; exploring different 
regulatory approaches; the importance of addressing 
environmental factors; and developing policy models that are 
both coherent and mutually supportive across different policy 
domains. Thus drug use may be an important topic for policy 
considerations in areas such as housing, employment, crime 
prevention and even security.
Taken together, these changes pose a clear challenge for the 
EMCDDA’s future work. We must ensure that we have 
epidemiological surveillance tools that are fit for purpose with 
respect to both current and future patterns of drug use and the 
associated health and social problems we will face in Europe. 
We must accompany them with communication and reporting 
channels that are innovative, timely and targeted, so that these 
findings can inform policies and actions better and faster.
We must also keep track of new research findings which are 
changing our understanding of how substance-use problems 
develop and which help identify and adopt new intervention 
options for both established and emerging problems. We must 
increase the value of our work by supporting the translation of 
new evidence into practice. This must be packaged together with 
an understanding of the factors important for ensuring successful 
implementation in the different contexts, systems and settings 
across the EU. We must also support the information needs of 
a more complex and changing policy debate and provide the 
evidence and tools that can facilitate Member States in selecting 
and evaluating different policy options.
Addressing these challenges remains the focus for our 
activities until 2025, and doing so will allow us to make 
a greater substantive contribution to a healthier European 
Union.
| Strategic objectives
1.  Maintain a state-of-the-art understanding of the 
extent of drug use, its patterns and trends and their 
impact on public health
A core challenge for the EMCDDA is to ensure that its tools 
and methods remain fit for purpose in relation to the changing 
nature of the European drugs phenomenon and 
accompanying information needs. This requires regular review 
and revision of existing instruments, as well as the 
development of new approaches. It will require work to 
anticipate future challenges and thereby allow the agency to 
make a long-term plan for developing instruments. The agency 
also needs to develop more complex reporting and analytical 
models that reflect drug problems defined by the consumption 
of multiple substances, including medicines and a rising 
EMCDDA STRATEGY 2025
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number of new synthetic substances bearing potentially high 
health risks. Furthermore, the European drugs problem is 
more and more linked to, and influenced by, global 
developments. Therefore, it will become increasingly 
important to identify trends and developments occurring in 
neighbouring countries and worldwide that could have an 
impact on the European situation.
Action areas:
1.1. Strengthen the core monitoring system
1.2.  Identify and develop new flexible and timely monitoring tools and 
approaches
1.3.  Understand the implications for public health of the developing 
international drugs problem
1.4. Identify future reporting needs
2.  Identify new drug-related health threats and support 
rapid response by the EU and its Member States
The EMCDDA has been entrusted with a key role in monitoring 
and responding to new psychoactive substances. In 
collaboration with our partners at national and EU levels 
(Europol and the European Medicines Agency) the agency 
operates the EU early warning system on new psychoactive 
substances (EWS). In addition to its monitoring role, where 
necessary, the EMCDDA responds in a timely manner to those 
substances that pose health concerns by undertaking 
scientific, evidence-based risk assessments. This area is 
developing rapidly and therefore requires the agency to be 
proactive and innovative in order to fulfil its responsibilities. 
Tools and approaches will have to be revised to take account 
of any changes in the legal framework in this area.
More generally, threat assessment and rapid reporting are 
likely to play a greater role in our work, reflecting the dynamic 
nature of the modern drugs problem and the accompanying 
need for rapid and targeted health responses. Areas of 
concern here include new risky behaviours; outbreaks of 
drug-related infectious diseases or other adverse health 
events; and new consumption patterns with implications for 
public health. Improving capacity in this area requires greater 
attention to be given to the development of multisource 
analytical models and to the use of innovative approaches to 
identify, track and monitor new drug trends.
Action areas:
2.1. Ensure the successful operation of the EU EWS
2.2. Ensure timely implementation of the risk assessment on NPS
2.3.  Develop innovative approaches and extend capacity to identify 
new trends
2.4.  Conduct threat assessments and rapid reporting exercises of 
new drug-related health threats
3.  Support interventions to prevent and reduce drug 
use, drug-related morbidity, mortality and other 
harms, and support recovery and social reintegration
The EMCDDA has an important responsibility to act as 
a catalyst for improving the quality and delivery of responses to 
reduce the health and social consequences associated with 
drug use. This requires the agency to keep abreast of new 
prevention, treatment and harm-reduction approaches. We 
also need to facilitate the identification and adoption of best 
practices, and to accompany this with improved understanding 
of what is necessary for successful implementation in diverse 
national contexts and settings. Special attention will be given 
to developing resources in areas where drugs have 
a significant impact on European public health, such as 
hepatitis C prevention and treatment, and overdose deaths.
Action areas:
3.1.  Maintain state-of-the-art understanding of effective interventions 
in both established and emergent drug-related problems
3.2.  Strengthen, maintain and develop the monitoring tools for 
describing the delivery of drug-related interventions
3.3.  Facilitate knowledge transfer, the adoption of best practice and 
successful intervention delivery
3.4.  Provide additional information resources to support policy 
development in areas particularly important for public health
4.  Support the development, implementation, 
monitoring and assessment of policies aimed 
at addressing the health and social consequences 
of drug use
An important priority for the agency is to provide support to 
those who define policy at both EU and national levels. Of 
particular importance here is our responsibility with respect to 
the EU Drug Strategy and the accompanying action plans on 
drugs (an activity which is also important for the other pillar of 
our strategy).
The EMCDDA will provide technical support, upon request, to 
the EU institutions and the Member States for their activities 
in international fora (e.g. at the United Nations General 
Assembly Special Session and the Commission on Narcotic 
Drugs).
Action areas:
4.1.  Support EU and national policy initiatives, with particular priority 
given to the EU Drug Strategy and its action plans
4.2.  Monitor and report on key national, European and international 
drug-related policy developments to facilitate an informed and 
up-to-date dialogue at EU level
4.3.  Maintain and develop methodologies and resources to support 
policy development and evaluation
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|  Goal 2: Contribute to a more secure Europe 
Under security, the EMCDDA’s new strategy has to respond to 
the same core challenges evident in the health area, namely 
the need to keep pace with a more dynamic situation; develop 
and maintain appropriate reporting tools; respond better to 
new threats; and provide support to policy and operational 
responses.
Although monitoring tools in the supply area are less well 
developed than for the demand area, significant progress is 
being made in improving the quality and comparability of 
existing core measures, and this work will remain a strategic 
priority. Collectively, these tools help describe important 
aspects of the European drug market and the focus will be to 
further develop and improve capacity to understand 
developments in drug markets and assess their security 
implications.
Current approaches, however, have limitations, and some 
important blind spots exist with respect to the areas in which 
the security implications of drug markets can be described. 
For this reason, the monitoring approaches in this area need 
to be further developed, in order to understand the key drivers 
of change and to keep pace with innovation. Examples of 
areas that remain underdeveloped include online drug sales 
(such as darknets or cryptomarkets), innovation in production 
processes, and the exploitation of commercial transport and 
delivery services. Importantly, to inform security responses, 
the information collected needs to be understood within the 
broader geographical and geopolitical context, recognising 
the interaction between the EU drug market and the larger 
European and global markets. Identifying and understanding 
important developments outside the EU is therefore vital for 
anticipating future drug-related security threats and for 
informing countermeasures.
The linked issue of drug-related crime is also a focus of the 
security pillar. The consequences of drug-related crime and 
how these are evolving is still not sufficiently understood. 
What is clear, however, is that the impact on society is 
considerable and that concerns are growing in some areas, for 
example in the interaction between drug trafficking and other 
serious security threats, such as terrorism, human trafficking 
and illicit financial flows. The 2016 EU Drug Markets Report, 
produced jointly with Europol, identified important knowledge 
gaps. This key resource, together with other sources, will 
further guide work in this area.
| Strategic objectives
1.  Provide a comprehensive, holistic and up-to-date 
understanding of the drug market in Europe
The EMCDDA and its partners have made significant progress 
in developing tools and methodologies to monitor the drug 
markets, including first estimates of the size — in terms of 
quantity and value — of the EU retail market for the main 
drugs. The agency will invest in improving, adapting and 
expanding these methodologies. It will do this by using 
existing networks and developing new data sources to 
augment the breadth of analysis in order to establish a state-
of-the-art monitoring system comprising a set of core routine 
data collection, complemented by contextual information, 
including ad hoc, opportunistic data-collection activities. This 
system will provide the essential elements for capturing, 
assessing and prioritising market signals for the timely 
identification of drug-related security threats, and will 
consequently provide support for the development of rapid 
responses. 
Action areas:
1.1.  Strengthen the core monitoring system on supply and supply 
reduction indicators
1.2.  Develop new and innovative data collection approaches to 
supplement the existing core data collection systems in this area
1.3.  Analyse the impact of the development of the international drugs 
situation on the European drug market
1.4.  Explore the drivers of innovation of synthetic drug production and 
their impact, and contribute to the European system on drug 
precursor monitoring
2.  Identify new drug-related security threats and 
support rapid response by the EU and 
its Member States
Identifying new drug-related security threats and transmitting 
this information rapidly so that appropriate responses can be 
developed is a key requirement for Europe to keep pace with 
the growing security challenges emerging in this area. Threat 
assessments will be conducted in the context of requests 
from stakeholders, in close collaboration with Europol, and in 
the framework of the EU Policy Cycle on Serious Organised 
International Crime. A key strategic challenge for the agency in 
this area is to continue to develop the information and 
analytical tools necessary to identify significant new 
developments. In particular our observational capacity needs 
to be extended to address innovation. This is particularly 
important with respect to synthetic drug production and how 
information technology developments are providing new 
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opportunities for the production, marketing and sale of both 
established and new drugs, including NPS.
Action areas:
2.1.  Provide threat assessments and strategic briefings related to 
transversal security threats linked to production and supply of 
drugs
2.2. Identify and communicate the threats associated with NPS
2.3.  Improve capacity to monitor innovation in the drug markets, in 
particular online drug markets and darknet drug sales
3.  Improve understanding of the nature and 
consequences of drug-related crime
The European security agenda highlights the need to 
understand the interactions that exist between drug-related 
crime and the operation of the drug market, on the one hand, 
and other areas of criminality, the activities of organised 
criminal groups and other serious security threats, on the other. 
This is a challenging area and one in which the EMCDDA needs 
to work closely with other European bodies with responsibilities 
in these areas, in particular Europol and Eurojust. Although 
some core monitoring tools exist, overall this remains a poorly 
developed area. Improving performance in this field, however, is 
important and this was highlighted in the EMCDDA–Europol 
2016 EU Drug Markets Report, which clearly suggests that 
threats in this area are increasing, in part because of the 
changing business models used by transnational organised 
crime groups. In addition to these major security threats, it is 
important to support the development of a broader 
understanding of the ramifications of the drug market, as these 
can represent significant hidden costs to society.
Action areas:
3.1.  Improve the monitoring of drug-related crime and associated 
responses and countermeasures
3.2.  Improve understanding of the links and interactions between 
drugs and serious criminality, including security threats
3.3.  Develop a broader conceptual framework on the wider societal 
impact of drug markets and drug-related crime
4.  Support policy and operational responses to the 
security challenges posed by drugs and drug markets 
at EU and national levels
The key added value that the EMCDDA can provide here is our 
knowledge and expertise on drug markets and their 
consequences. The provision of objective, factual and reliable 
information and analysis will support capacity building within 
the EU and beyond; it will assist decision- and policymakers in 
devising responses to emerging drug-related threats; and it 
will establish baseline data that will support the evaluation of 
supply-side interventions.
Action areas:
4.1. Support the EU Policy Cycle on Serious Organised International 
Crime and provide expertise on the European Multidisciplinary 
Platform against Criminal Threats (EMPACT) drug priority areas
4.2. Increase the effectiveness and impact of EU actions in the 
security area
4.3. Develop capacity for evaluating, upon request, law-enforcement 
responses to drug supply interventions
I  The environment for successful delivery: the EMCDDA’s business drivers
The success of this strategy will rely on our capacity to provide 
our stakeholders with services that match their evolving 
needs. This will be possible only if the agency is performing 
optimally, both substantively and operationally. This requires 
us to ensure that the EMCDDA is forward looking, analytical 
and resource-efficient, and focused on delivery.
The results of the strategic and critical analysis carried out as 
part of the preparatory work for developing the Strategy 2025 
highlighted that the organisation has key strengths, 
particularly in its human capital. In addition, however, 
a number of important internal and external challenges were 
identified that if not adequately addressed could affect the 
agency’s performance.
Based on this analysis, we have identified a set of business 
drivers (B.1–B.4) that address external and internal factors 
critical for our performance: the institutional framework, 
effective partnerships, scientific capacity and the agency’s 
overall management capabilities.
These four business drivers are interlinked and jointly 
contribute to the successful delivery of our services (Figure 3).
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B.1. Institutional
Anticipate, and respond promptly to, institutional 
developments and needs
The EMCDDA operates in a complex institutional environment 
and its capacity to respond promptly to changing 
developments and needs is therefore a critical requirement for 
optimal performance. This requires a proactive approach to 
identifying where our work can provide value and ongoing 
attention to ensuring that services are delivered in the 
appropriate form. Understanding needs clearly, 
communicating effectively and using targeted delivery 
channels are central to serving our stakeholders successfully. 
As advances in technology present new opportunities and 
also bring with them new expectations, we will need to 
regularly review our services to ensure they remain relevant.
Action areas:
B.1.1.  Continue to analyse the external environment and how it 
relates to current and future stakeholder needs
B.1.2.  Configure services to ensure they are timely, of a high 
professional standard and delivered in a form coherent with our 
stakeholders’ needs
B.1.3.  Prepare the agency for ongoing and potential future revisions 
of its mandate
B.2. Partnership
Strengthen the European Drug Information System through 
effective and mutually beneficial partnerships and 
synergies with our data providers, communities of 
knowledge, relevant European and international 
organisations and cooperation with third countries
The EMCDDA can be the leading EU provider of evidence on 
drugs only if we develop our services in partnership with the 
national, European and international actors working in the 
drugs field. We recognise that the fundamental principles for 
effective partnership include transparency, mutual benefit and 
clarity with respect to roles and responsibilities and are 
committed to respecting them.
In the area of data collection, and for maintaining an ongoing 
dialogue with national experts and data providers, our main 
partners are the Reitox network of national focal points 
(NFPs). The Reitox network acts as a central conduit for 
structured data sets required by the EMCDDA and supports 
the development of harmonised and comparable data 
collection tools. The focal points also provide an important 
resource for supporting the standing technical expert groups 
needed for EMCDDA activities. The EMCDDA recognises the 
importance of the Reitox network in ensuring a European drug 
information system and also that involvement in European 
activities should provide tangible benefits and value at the 
national level. A new Reitox Development Framework, which 
will define the main priorities of the network and guide its 
future work, is being developed.
In addition to Reitox, the EMCDDA needs to work directly with 
a number of specialist data providers and research 
collaborations, such as the European School Survey Project 
on Alcohol and Other Drugs (ESPAD) Group.
At the European and international levels, pursuing synergies 
and maintaining effective working arrangements with other 
relevant EU agencies and international organisations, 
especially members of the UN family active in drugs issues, 
will always be critical for the EMCDDA’s performance. 
Cooperation with the agencies working in the Justice and 
Home Affairs area (particularly Europol, Eurojust and the 
European Union Agency for Law Enforcement Training, 
CEPOL) and in the health field (namely the European 
Medicines Agency and the European Centre for Disease 
Prevention and Control) will remain a priority.
The activities in the area of international cooperation will be 
guided by the new EMCDDA International Cooperation 
Framework, which is planned to be developed in 2017 and 
submitted for adoption to the Management Board. This will 
update the EMCDDA Strategy on International Cooperation 
adopted in 2007.
FIGURE 3
The EMCDDA’s business drivers
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Action areas:
B.2.1.  Develop, jointly with the NFPs, the new Reitox Network 
Development Framework, and support its implementation by 
the NFPs
B.2.2.  Strengthen national drug expert networks, in cooperation with 
the NFPs, and develop if necessary new networks
B.2.3. Strengthen cooperation with EU and international partners
B.3. Scientific capacity
Have in place the scientific capacity (resources, processes 
and tools) to meet current analytical needs, and innovate to 
keep pace with changes in the drugs situation and the 
corresponding institutional needs
The multifaceted nature of the drugs situation requires the 
EMCDDA to have both sufficient in-house expertise and 
access to experts working elsewhere to ensure adequate 
scientific capacity for its work. As the information needs of the 
agency are changing, this also implies that it must develop 
expertise in new areas that are required to fulfil its mandate. 
As, over the course of the strategy, scientific developments 
are likely to impact on our understanding of the aetiology and 
epidemiology of drug problems and result in new 
pharmacotherapies and social interventions, the agency will 
have to invest more in maintaining an ongoing dialogue with 
the research and scientific community, in both the drugs area 
and related disciplines, such as addiction science and 
criminology. The EMCDDA’s Scientific Committee is an 
important resource in this respect.
The growing demands placed on the agency mean that the 
EMCDDA’s scientific teams will need to adopt working 
processes that are efficient, flexible and driven by clear 
priorities.
Action areas:
B.3.1. Maintain and develop the EMCDDA’s scientific capacity and 
ensure that it reflects the expertise required for the agency to fulfil its 
mandate
B.3.2. Optimise the allocation and use of scientific resources
B.3.3. Strengthen the quality management of scientific activities
B.3.4. Strengthen dialogue and cooperation with the scientific 
community and centres of excellence in the drugs field
B.4. Management
Ensure that the organisational structure and supporting 
processes are optimal, to deliver efficient and high-quality 
services
Excellent performance cannot be achieved if it is not 
supported by a healthy work environment and by good 
governance. It also requires that support services, such as 
administration and information and communication 
technologies, perform at a high level. The EMCDDA will 
therefore ensure that the optimal organisational structure and 
supporting processes are in place and that their performance 
is regularly reviewed and developed in order to maintain 
a business environment commensurate with the long-term 
requirements of the strategy.
Action areas:
B.4.1. Put in place the new organisational structure and other 
measures necessary for the successful implementation of the 
Strategy 2025
B.4.2. Further improve cost-effectiveness and optimal allocation of 
resources, reflecting the priorities identified in the Strategy 2025
B.4.3. Strengthen performance management at all levels
B.4.4. Improve people management and implement a sustainable 
staff training and development programme
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Roadmap 2020
The tables below present the key milestones for the EMCDDA to implement the strategy until 2020. Unless otherwise indicated, 
the milestones are to be achieved by 2020.
| Strategic objectives
Goal: Healthier Europe
Strategic objectives Key milestones 2020
1. Maintain a state-of-the-art understanding of the 
extent of drug use, its patterns and trends and their 
impact on public health
New conceptual framework for data collection in place:
■■ systemic review (2019)
■■ review of performance of individual reporting tools and gaps analysis (2019)
Technical infrastructure capacity: specifications for new Fonte 2 architecture:
■■ data collection processes mapping (2017)
■■ action plan modelling, quality assurance and risk management for data collection 
(2018–20)
EMCDDA report on future priorities for drug monitoring and reporting to support policy 
dialogue on drugs:
■■ foresight exercise (2017–20)
• inception of Lisbon Addictions (2017)
• technical review of Lisbon Addictions (2019)
• policy workshop (2020)
2. Identify new drug-related health threats and support 
rapid response from the EU and its Member States
EWS and risk assessment mechanisms (supporting tools, processes and activities) 
operating under the new legal basis:
■■ measures necessary to comply with the new legal basis (2018)
■■ European Database on New Drugs upgraded to reflect new reporting needs (2019)
■■ guidelines, processes and tools updated (2020)
New integrated framework for threat identification and reporting in place (health pillar 
elements):
■■ rapid information assessment tools (developed by 2018 and tested by 2020)
■■ communication model for threat and rapid reporting
3. Support interventions to prevent and reduce drug 
use, drug-related morbidity, mortality and other harms, 
and support recovery and social reintegration
Consolidated evidence and implementation framework to support delivery of drug-
related interventions:
■■ holistic conceptual model for identifying and planning responses (European Drug 
Responses Report – EDRR 2017) supported by update of Best practice portal (BBP)
■■ extension of BBP platform to include identification of effective programme examples 
(2017–20)
■■ set of implementation support tools developed for selected response areas (2017–20)
Tools for self-accreditation of quality standards available
Operationalise existing minimum quality standards for monitoring implementation levels 
(2017–19)
State-of-the-art review of new challenges and opportunities for responding to drug 
problems (EDRR 2020) informed by foresight exercise
4. Support the development, implementation, 
monitoring and assessment of policies aimed at 
addressing the health and social consequences of 
drug use
EMCDDA reporting system aligned to support EU-level policy articulation, in particular 
the new EU action plan 2017–20, the 2013–20 EU strategy evaluation and formulation of 
the new EU Drug Strategy 2021–27
Portfolio of tools and services to support policy development, implementation and 
evaluation in the Member States and priority third countries
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Goal: More secure Europe
Strategic objectives Key milestones 2020
1. Provide a comprehensive, holistic and up-to-date 
understanding of the drug market in Europe
Assessment of progress made in core and new tools, indicators embedded in the overall 
EMCDDA conceptual framework for data collection and analysis, and priority areas for 
future needs identified
Strategic overview of the European drug market, identification and assessment of internal 
and external drivers:
■■ EU Drug Markets Report (EDMR) (2019)
■■ Project Inter-LINK (starting in 2018)
2. Identify new drug-related security threats and 
support rapid response by the EU and its Member 
States
New integrated framework for threat identification, assessment and reporting in place 
(supply pillar elements):
■■ threat assessment tools (developed by 2018 and tested by 2020)
■■ communication model for threat and rapid reporting (2019‒20)
3. Improve understanding of the nature and 
consequences of drug-related crime
Overarching conceptual framework for monitoring drug-related crime, its wider impact 
and what constitutes effective countermeasures
4. Support policy and operational responses to the 
security challenges posed by drugs and drug markets 
at EU and national levels
EMCDDA, working with Europol, is recognised as an integral drug information resource to 
support policy and action at EU level on serious organised international crime
| Business drivers
Business drivers Key milestones 2020
External Institutional 
Anticipate, and respond promptly to, 
institutional developments and needs
EMCDDA positively evaluated and follow-up recommendations addressed 
Framework for proactively identifying and responding to stakeholders’ needs in place 
Revised EMCDDA Regulation (EWS and risk assessments) implemented, rules of 
procedures and guidelines published 
Strategic analysis of consequences of potential future changes in EMCDDA Regulation 
on the basis of EMCDDA and EU Strategy and Action Plan evaluations
Partnership 
Strengthen the European Drug 
Information System through effective 
and mutually beneficial partnerships 
and synergies with our data providers, 
communities of knowledge, and 
relevant European and international 
organisations and cooperation with 
third countries
New Reitox Network Development Framework
Corporate network and partners’ management approach in place
Joint work programmes with partner European and international organisations updated in 
line with priorities for implementation of the strategy in 2016–20
Internal Scientific capacity
Have in place the scientific capacity 
(resources, processes and tools) to 
meet current analytical needs, and 
innovate to keep pace with changes in 
the drugs situation and the 
corresponding institutional needs
Project management planning and implementation approach in place for scientific areas
Mechanism for cooperation with established scientific centres of excellence in the drugs 
field established
Comprehensive quality assurance framework for scientific activities, informed by the 
recommendations of audits where relevant
Management
Ensure that the organisational structure 
and supporting processes are optimal, 
to deliver efficient and high-quality 
services
New organisational structure fully operational (2018)
Staff development programme in place
Overall project management framework operational and 80% of the Level 1 (L1) and 
Level 2 (L2) activities in the SPD implemented as projects
Planning instruments fully aligned with the Strategy 2025 (2018)
Roadmap 2020 assessed and Roadmap 2025 prepared
21
Annexes
|  ANNEX 1 At a glance: the EMCDDA’s strategic objectives and accompanying action areas
GOALS STRATEGIC OBJECTIVES ACTION AREAS
Healthier 
Europe
1. Maintain a state-of-the-art 
understanding of the extent of 
drug use, its patterns and 
trends and their impact on 
public health
1.1. Strengthen the core monitoring system: (a) critically review and develop, as needed, 
the data collection tools to ensure that they remain fit for purpose; (b) support national 
reporting capacity necessary for routine reporting
1.2. Identify and develop new flexible and timely monitoring tools and approaches to 
ensure that the monitoring system reflects contemporary drug patterns and their 
implications for public health
1.3. Better understand the implications for public health of the developing international 
drugs problem, with special attention to the countries bordering the European Union, 
and within the agency´s mandate
1.4. Identify future reporting needs through a foresight exercise and appropriate follow-up 
activities
2. Identify new drug-related health 
threats and support rapid 
response by the EU and its 
Member States
2.1. Ensure the successful operation of the EU EWS
2.2. Ensure timely and high-quality implementation of the risk assessment on NPS
2.3. Develop innovative approaches to identifying and reporting on new trends, and 
enhance the EMCDDA’s capacity for timely data collection and analysis
2.4. Conduct threat assessments and rapid reporting exercises of new drug-related health 
threats in order to facilitate appropriate responses (in collaboration with partners, as 
appropriate)
3. Support interventions to 
prevent and reduce drug use, 
drug-related morbidity, 
mortality and other harms, and 
support recovery and social 
reintegration
3.1. Follow developments from basic research, applied research and implementation 
science to maintain state-of-the-art understanding of what constitute effective 
interventions in both established and emergent drug-related problems
3.2. Strengthen, maintain and develop the monitoring tools required for describing the 
delivery of drug-related interventions: (a) in established areas and settings; (b) in new 
settings and developmental areas
3.3. Facilitate knowledge transfer, the adoption of best practice and successful 
implementation, by developing state-of-the-art resources for professionals and 
supporting and developing training and capacity-building activities
3.4. Provide additional information resources to support decision-making and programme 
development in areas particularly important for public health, where innovations are 
becoming available or the knowledge base is rapidly changing (such as hepatitis 
C treatment, overdose prevention, new pharmacotherapies, e-health and interventions 
targeting hard-to-reach populations) or where new evidence reviews have become 
available
4. Support the development, 
implementation, monitoring 
and assessment of policies 
aimed at addressing the health 
and social consequences of 
drug use
4.1. Support as requested EU and national policy initiatives within the EMCDDA’s areas of 
competence, with particular attention given to the implementation of the EU Drug 
Strategy and its action plans
4.2. Monitor and report on key policy developments, occurring nationally, at EU level and 
internationally, to facilitate an informed and up-to-date dialogue
4.3. Maintain and develop resources to support policy formulation and evaluation (in close 
coordination with the support to policy provided in the supply area)
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GOALS STRATEGIC OBJECTIVES ACTION AREAS
More secure 
Europe
1. Provide a comprehensive, 
holistic and up-to-date 
understanding of the drug 
market in Europe
1.1. Strengthen the core monitoring system: improve quality and coverage in the 
implementation of supply and supply reduction indicators in the Member States and 
their supporting tools, networks and processes
1.2. Develop new and innovative data collection approaches to increase the scope and 
coverage of analysis, and provide a cost-effective and practical solution to supplement 
existing core data-collection systems in this area (e.g. open source intelligence; 
internet monitoring; web surveys)
1.3. Improve understanding of the impact on the European drug market of developments in 
the international drugs situation, with particular attention given to the countries 
bordering the EU
1.4. Support a better strategic understanding of the drivers of innovation in synthetic drug 
production and their impact, including routes of synthesis and source chemicals, and 
contribute to the European system on drug precursor monitoring, together with the 
European Commission and Europol
2. Identify new drug-related 
security threats and support 
rapid response from the EU and 
its Member States
2.1. Provide threat assessments related to transversal security threats linked to the 
production and supply of drugs
2.2. Identify and communicate the threats associated with NPS with respect to sourcing, 
production, transit and marketing, and ensure vigilance and follow-up on threats 
related to the emergence of newly controlled NPS on the drug market
2.3. Improve capacity to monitor innovation in the drug market and its impact, with special 
attention given to the development of online drug markets and darknet drug sales
3. Improve understanding of the 
nature and consequences of 
drug-related crime
3.1. Improve the monitoring of drug-related crime and associated responses and 
countermeasures and their impact
3.2. Contribute to an improved understanding of the links and interactions between drugs 
and serious criminality, including security threats, such as illegal financial flows, 
corruption, trafficking in other illicit cargoes and terrorism
3.3. Support the development of a broader conceptual framework on the wider societal 
impact of drug markets and drug-related crime, including environmental impact, 
implications for community safety and possible unintended negative consequences of 
interventions
4. Support policy and operational 
responses to the security 
challenges posed by drugs and 
drug markets at EU and national 
levels
4.1. Support the EU Policy Cycle on Serious Organised International Crime and provide 
expertise on the EMPACT drug priority areas (through threat assessments, provision of 
expertise and training). A priority task for the EMCDDA is to maintain an overview of EU 
drug markets, their ramifications and responses
4.2. Increase the effectiveness and impact of EU actions in the security area including by 
(a) strengthening/establishing networks of field experts, academics, law-enforcement 
officials, etc. and (b) defining criteria for identifying, understanding and prioritising 
emerging threats (including external, current and future) stemming from drug market 
activity, integrating uncertainty, projected trends and scenario planning
4.3. Develop capacity for supporting the evaluation, upon request, of law-enforcement 
responses to drug supply interventions (in close coordination with policy support 
provided to health interventions)
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|  ANNEX 2 At a glance: the EMCDDA’s business drivers and accompanying action areas
ENVIRONMENT BUSINESS DRIVERS ACTION AREAS
External
B.1. Institutional
Anticipate, and respond promptly to, institutional 
developments and needs
B.1.1.  Continue to analyse the external environment and how 
it relates to current and future stakeholder needs
B.1.2.  Configure services to ensure they are timely and are 
delivered professionally and in a form coherent with 
our stakeholders’ needs
B.1.3.  Prepare the agency for ongoing and potential future 
revisions of its mandate, in line with the 
recommendations of the external evaluation to be 
performed in 2018, and the conclusions of the 
evaluation of the EU Drugs Strategy and Action Plan
B.2. Partnership
Strengthen the European Drug Information System through 
effective and mutually beneficial partnerships and synergies 
with our data providers, communities of knowledge, and 
relevant European and international organisations and 
cooperation with third countries
B.2.1.  Develop, jointly with the NFPs, and guided by the 
EMCDDA Strategy 2025, the new Reitox Network 
Development Framework, and support its 
implementation by the NFPs
B.2.2.  Strengthen national drug expert networks and 
develop, if necessary, new networks to ensure that the 
agency has sufficient expertise to accomplish the 
strategy’s objectives
B.2.3.  Strengthen cooperation with EU and international 
partners in line with work priorities defined by the 
Strategy 2025 and emerging needs of stakeholders
Internal
B.3. Scientific capacity
Have in place the scientific capacity (resources, processes and 
tools) to meet current analytical needs, and innovate to keep 
pace with changes in the drugs situation and the 
corresponding institutional needs
B.3.1.  Maintain and develop the EMCDDA’s scientific 
capacity and ensure it reflects the expertise required 
for the agency to fulfil its mandate
B.3.2.  Optimise the allocation and use of scientific resources 
through clear prioritisation, adoption of more flexible 
working practices and the use of external resources 
where cost-efficient
B.3.3.  Strengthen the quality management of scientific 
activities
B.3.4.  Strengthen dialogue and cooperation with the 
scientific community and centres of excellence in the 
drugs field to ensure that the EMCDDA maintains 
a state-of-the-art understanding of developments in its 
areas of competence
B.4. Management
Ensure that the organisational structure and supporting 
processes are optimal, to deliver efficient and high-quality 
services
B.4.1.  Put in place the new organisational structure and other 
measures necessary for successful implementation of 
the Strategy 2025
B.4.2.  Further improve cost-effectiveness and optimal 
allocation of resources, reflecting the priorities 
identified in the Strategy 2025
B.4.3.  Strengthen performance management at all levels
B.4.4.  Improve people management and implement 
a sustainable staff training and development 
programme to ensure that the EMCDDA has the 
committed, skilled and motivated human resources it 
requires to achieve its long-term objectives
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(http://eeas.europa.eu/delegations/index_en.htm);  
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
About EMCDDA Strategy 2025
This strategy sets out an ambitious course of travel for 
the agency to 2025. It presents a vision to contribute to 
a healthier and more secure Europe, through better 
informed drug policy and action. Adopted unanimously 
by the agency’s key stakeholders in 2016, the strategy 
is the result of a year-long, in-depth analysis of the 
environment in which the EMCDDA operates. This 
analysis focused, in particular, on customer needs and 
a critical review of our internal capacity to meet them.
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